An analysis of 5-year survival of patients with cervical cancer treated with curable 
intent in relation to selected prognostic factors. A population-based study by Bielska-Lasota, M.
Original papers • Artyku∏y oryginalne
NOWOTWORY Journal of Oncology • 2005 • volume 55
Number 1 • 23–33
An analysis of 5-year survival of patients with cervical cancer treated 
with curable intent in relation to selected prognostic factors.
A population-based study
Magdalena Bielska-Lasota
A i m.  The study was aimed at evaluating 5-year survival and the selected prognostic factors in radically treated cervical cancer
patients living in the provinces of Kielce, Opole, and Warsaw. These regions are characterised by diversified mortality rates and
diversified access to cancer prevention and treatment.
M a t e r i a l.  Three cohorts of, altogether, 738 women who had contracted the disease in the years 1990-1996 and were
identified using population data collected by the Cancer Registries from the voivodeships of Kielce (K), Opole (O) and
Warsaw (W).
M e t h o d.  Age-standardised 5-year survival rates and the relative excess risk of death (RER) were calculated using the life-
table methods and Hakulinen’s multi-variant regression models.
R e s u l t s.  The regions were found to differ significantly in the proportion of patients treated in different advancement of the
disease, mainly the early stages (I: K – 64.6%, O – 39.4%, W – 44.0%), but not in age group distribution or histopathological
diagnosis. The overall 5-year survival rate was 71.1% and by stages amounted to: I – 88.5%, II – 57.7%, III – 43.6%. In the
regions under study, survival reached: K – 73.5%, O – 60.7%, W – 75.9%. In Stage I differences were only insignificant,
although meaningful, for Stage II (K –51.0%, O – 43.0%, W – 69.7%) and, also in the youngest age groups (for the age below
45 survival rates were: K – 73.2%, O – 50.5%, W – 82.2%).
Also the “waiting time” for treatment was significantly different: K – 63.2; O – 61.5; W – 52.4 days. However, there were no
marked differences in the duration of teleradiotherapy. The multi-variant analysis showed that the factors responsible for
significant increase in RER include: disease advancement (p<0.0001), delay in treatment by more than 60 days (p=0.04), and
place of residence related to place of treatment (p<0.03).
C o n c l u s i o n s.  The 5-year survival rates of cervical cancer patients in Poland differ from region to region not only due to the
proportion of stages of advancement, but also as a consequence of different standards of treatment, mainly of patients in Stage
II and Stage III.
Analiza pi´cioletnich prze˝yç chorych na raka szyjki macicy leczonych radykalnie 
w zale˝noÊci od niektórych czynników rokowniczych.
Badanie populacyjne
C e l.  Ocena 5-letnich prze˝yç oraz niektórych czynników rokowniczych u chorych na raka szyjki macicy leczonych radykalnie,
zamieszka∏ych w województwach kieleckim i opolskim oraz w Warszawie – regionach o zró˝nicowanej umieralnoÊci, a tak˝e
dost´pnoÊci profilaktyki i leczenia onkologicznego.
M a t e r i a ∏.  Materia∏ stanowi∏y trzy kohorty liczàce ∏àcznie 738 kobiet, które zachorowa∏y w latach 1990-96 i zosta∏y
zidentyfikowane na podstawie danych populacyjnych Rejestrów Nowotworów w Kielcach (K), Opolu (O) oraz w War-
szawie (W).
M e t o d y.  Wskaêniki 5-letnich prze˝yç, standaryzowane wed∏ug wieku, oraz wzgl´dny wzrost ryzyka zgonu (RER) obliczono
stosujàc metod´ tabel trwania ˝ycia i wielowymiarowej regresji Hakulinena.
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Introduction
Cancer of the uterine cervix in Poland continues to pose
a massive health problem. It is responsible for about 2,000
deaths each year and the respective mortality rates are:
the crude rate 10.0/105 and standardised rate: 6.8/105 [1].
Owing to prevention achievements and tremendous
diagnostic and treatment progress in many countries, the
number of deaths caused by this cancer has significantly
declined with the mortality rates dropping down to about
4/105 [2].
Results of a study [3] done on data covering all the
cervical cancer cases in the voivodships of Kielce and
Opole, and in the City of Warsaw are consistent with
reports saying that the 5-year survival rates in Poland are
rather low [4-6], and the disease advancement and
diagnosis of adenocarcinoma are the most important
prognostic factors in this disease [7-9].
Clinical studies emphasize significance of prognostic
factors dependent on cancer disease, and among them,
those most important are: the stage of disease, tumour
size, histological diagnosis, and presence of metastases
in lymphatic nodules and then, the depth and extent of
infiltration [10]. Factors, dependent on the patient
condition include: his performance status, inclusive of
the level of haemoglobin. Factors, depending on the
treatment are: dose and duration of radiotherapy,
application of brachytherapy and cisplatin. In clinical
studies, the role of adenocarcinoma diagnosis and
patient’s age are controversial as independent prognostic
factors.
The unfavourable proportion of early cancer stages
in Poland can, to some extent, explain the low 5-year
survival rate values. However, the regional differentiation
of the survival rates evaluated for the same advancement
stages (especially Stage I and II) suggests some diversity
in treatment standards [3]. This part of the analysis
attempts to evaluate the effect of some factors related
to the treatment.
The aim of the study was to compare the survival of
patients with cervical cancer receiving curative treatment;
living in the voivodships of Kielce, Opole, and in Warsaw,
as well as to evaluate the effect of time between diagnosis
and beginning of treatment, and also the number of days
of teleradiotherapy on the prognosis for these patients,
taking into consideration the stage of disease, histological
diagnosis, and the patient’s age at diagnosis.
Material and method
Three cohorts were created – altogether 738 women with
invasive cervical cancer – 206 from the Kielce and 193 from the
Opole voivodships and 339 from Warsaw City – diagnosed
between the years 1990 and1996 as the primary malignancy.
The patients were referred for radical treatment, which was
completed in line with the plan, that is, they received the full
prescribed teleradiotherapy and brachytherapy doses of 85-90 Gy
(of this, at least 46 Gy in teleradiotherapy) administered to
point A in fractioned doses and/or were subject to radical
surgery.
The patients were identified using the Cancer Registry
data in Kielce, Opole and Warsaw. The demographical data and
clinical information about the patients were collected by persons
with medical background, in a uniform way, following a com-
mon, earlier provided protocol. The data was checked for
correctness by the regional study co-ordinator. The investigators
used Cancer Registry data, medical records, and other relevant
medical documentation obtained from all the hospitals and
other places where these documents could be found. The
documentation was available for 88% of the patients reported to
Cancer Registries whose files carried comment on curative
treatment being planned. In the Kielce voivodship, in the files of
80 patients with a diagnosis of cervical cancer Stage I the dates
for the beginning of treatment were missing hence, these patients
were excluded from the delay treatment analysis and from the
duration of radiotherapy analysis.
The clinical data included: the clinical advancement stage
acc. to the FIGO classification, histological diagnosis, date of
treatment onset, and the methods of treatment. In case of
patients receiving radiotherapy it was checked whether they had
received the planned radiotherapy doses. The time from
diagnosis to the beginning of treatment was calculated using
the earliest date of reporting to the Cancer Registry and the
date of treatment beginning, which were extracted from the
patients’ medical records (if the diagnosis date in the medical
records was earlier than that in the Cancer Registries, it was
corrected with the appropriate methods).
The patients were treated with surgical methods, irra-
diation from external fields and brachytherapy as standalone
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W y n i k i.  Badane regiony by∏y znacznie zró˝nicowane pod wzgl´dem proporcji chorych w poszczególnych stopniach zaawan-
sowania choroby, g∏ównie stopni wczesnych (I: K – 64,6%, O – 39,4%, W – 44,0%). Nie by∏o natomiast znaczàcych ró˝nic
w grupach wieku i w rozpoznaniu histopatologicznym. Wskaênik 5-letnich prze˝yç ogó∏em wynosi∏ 71,1%, zaÊ wed∏ug stopni
zaawansowania: I – 88,5%, II – 57,7%, III – 43,6%. W badanych regionach prze˝ycia wynosi∏y: K – 73,5%, O – 60,7%, W –
75,9%). W stopniu I zró˝nicowanie by∏o niewielkie, znaczàce zaÊ w stopniu II (K – 51,0%, O – 43,0%, W – 69,7%), oraz
w najm∏odszych grupach wieku (u chorych m∏odszych ni˝ 45 lat prze˝ycia wynosi∏y: K – 73,2%, O – 50,5%, W – 82,2%). Rów-
nie˝ „czas oczekiwania” na leczenie by∏ istotnie zró˝nicowany i wynosi∏: K – 63,2; O – 61,5; W – 52,4 dni. Nie stwierdzono na-
tomiast znacznych ró˝nic w czasie trwania teleradioterapii. Analiza wielowymiarowa wykaza∏a, ˝e czynnikami istotnie zwi´k-
szajàcymi RER sà: zaawansowanie choroby (p<0,0001), opóênienie leczenia ponad 60 dni (p=0,04) oraz miejsce zamiesz-
kania, co wiàza∏o si´ z miejscem leczenia (p<0,03).
W n i o s k i.  Pi´cioletnie prze˝ycia chorych na raka szyjki macicy w Polsce sà zró˝nicowane regionalnie, nie tylko w wyniku
ró˝nej proporcji stopni zaawansowania, ale tak˝e wskutek ró˝nych standardów leczenia, g∏ównie chorych w stopniu II i III.
Key words: cervical cancer, population-based survival, prognostic factors
S∏owa kluczowe: rak szyjki macicy, prze˝ycia populacyjne, czynniki rokownicze
or in combination, according to the various protocols (different
sequences of methods applied, different radiation sources,
intervals pre-scheduled in therapy), which rendered the
treatment methods incomparable. Hence, in the analysis of
treatment time as a prognostic factor the study was limited to the
number of days of teleradiotherapy. Based on data from
literature, the teleradiotherapy time was considered as extended
if it was longer than 35 working days (7 weeks) [11, 12].
The effects of the following prognostic factors were
evaluated: FIGO clinical advancement Stages I, II, and III, age
groups: 15-44, 45-64, 65-74, and 75 and over, diagnosis of
squamous cell carcinoma and adenocarcinoma, the number of
days from diagnosis to beginning of treatment: up to 30, 30-60,
and over 60, as well as the place of inhabitation: voivodships of
Kielce and Opole, and the city of Warsaw.
The patients were followed up for 5 years. Missing data
concerning their date of death or the last observation were
completed with data obtained from the Census Office.
According to the methods applied for multi-centre studies
and in order to allow for comparisons, statistical analysis was
performed by one team using uniform methodology recommen-
ded by WHO-IARC for population studies on cancer [13]. The
collected data was checked and processed separately for each
Cancer Registry. SAS (the SAS software was used under the
Licence Agreement No. 89601 which allows the Maria Sk∏o-
dowska-Curie Cancer Center and Institute of Oncology to use
this software free of charge) software was used in the statistical
analysis. For the evaluation of prognostic factors distribution
we applied the Chi square test, variance analysis, and Tykey’s
multiple comparison test. The statistical significance level was
adopted as p≤0.05.
Software SURV2, recommended for computing population
survival was used for the calculation of relative 5-year survival
rates and the 95% confidence interval [14, 15]. For the
computation of relative survival rates we used life expectancy
tables specific for Warsaw, while calculations for the voivodships
of Kielce and Opole, relied on average values for Poland.
The relative excessive risk of death (RER) was calculated
with the method of multi-variant regression analysis, modified by
Hakulinen and Tenkanen, and recommended for studies based
on data from population-based cancer registries where the death
cause is usually unknown [16]. This method allows to evaluate
the difference between risk of death in the study group and in
the reference group, this risk being taken into consideration for
the general population in the region under study.
Results
Pa t i e n t s  c h a r a c t e r i s t i c s
The description of patients who had completed treatment
in tune with the protocol assigned to the study regions is
presented in Table I. The largest group of the radically
treated patients was diagnosed as Stage I of the disease
advancement (358 or 48.5%), the second largest – as
Stage II (284 or 38.5%). Ninety-six patients (13.0%) were
treated at Stage III of the disease. The largest age group
was that between 45 and 64 years (48.6%) and younger,
under 44 (31.8%). Squamous cell carcinoma represented
89.5% and adenocarcinoma – 7.5% of cases.
The study regions differed significantly as to the
proportion of patients in various stages of disease
advancement (p<0.001). Patients with Stage I cervical
cancer from the voivodship of Kielce made up the largest
group – 64.6%, from Warsaw – 44.0% and from the
Opole voivodship – 39.4%. There were no significant
differences in the distribution of age groups (p=0.11)
and between the proportions of the squamous cell and
adenocarcinoma (p=0.71).
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Table I. Patient characteristics
Kielce voivodship Opole voivodship Warsaw All p
Number of patients
%
Stage of disease
I 133 76 149 358
64.6 39.4 44.0 48.5
II 62 83 139 284
30.1 43.0 41.0 38.5
III 11 34 51 96
5.3 17.6 15.0 13.0
<0.001
Age group (years)
15-44 62 60 113 235
30.1 31.1 33.3 31.8
45-64 97 104 158 359
47.1 53.9 46.6 48.6
65-74 35 28 53 116
17.0 14.5 15.6 15.7
75+ 12 1 15 28
5.8 0.5 4.5 3.9
0.11
Histopathological diagnosis
squamous cell carcinoma 185 176 300 661
89.8 91.2 88.5 89.5
adenocarcinoma 14 14 27 55
6.8 7.3 8.0 7.5
others and NS 7 3 12 22
3.4 1.5 3.5 3.0
0.71
Table II shows the proportions of patients by disease
advancement stages and age groups. The share of Stage I
cancer declined with patient age, while the number of
more advanced stages increased. It should be noted that
the proportions of advancement stages were found to be
particularly unfavourable in the youngest women living in
the voivodship of Opole. When compared with the other
regions, the proportion of Stage I patients was around
10 percent points, whereas Stage II patients made about 7
percent points, although this difference was not
statistically significant (p=0.52). Similarly, within the
same area we found an unfavourable proportion of
advancement stages in the groups aged 45-64 years.
T h e  5 - y e a r  s u r v i v a l s
The 5-year survival rate for all the patients was 71.1%
and it varied from the most favourable in Warsaw -75% to
the lowest values in the voivodship of Opole – 60.7%.
The survival rate in the voivodship of Kielce was 73.5%.
As can be seen from Table III, the relative 5-year
survival rates were dropping with disease advancement
stage and amounted to: I – 88.5%, II -57.7%, and III –
43.6%, and in patients with the diagnosis of adeno-
carcinoma (59.9%), as compared to squamous cell
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Table II. Stages of disease by age group and place of living
I II III p
Number of patients
%
15-44
Kielce voivodship 22 14 3
56.4 35.9 7.7
Opole voivodship 25 23 7
45.5 41.8 12.7
Warsaw 61 38 14
54.0 33.6 12.4
0.52
45-64
Kielce voivodship 26 27 5
44.8 46.6 8.6
Opole voivodship 44 44 18
41.5 41.5 17.0
Warsaw 66 71 21
41.8 44.9 13.3
0.96
> 65 
Kielce voivodship 5 21 3
17.2 72.4 10.3
Opole voivodship 7 16 9
21.9 50.0 28.1
Warsaw 22 30 16
32.4 44.1 23.5
0.12
Table III. Five-year relative survival rates by stage of disease, age group and morphology
Kielce voivodship Opole voivodship Warsaw All
Number of patients
5-year relative survival rate %
(95% PU)
Stage of disease (FIGO)
I 133 76 149 358
86.5 88.7 90.2 88.5
(78.7-92.4) (78.8-95.2) (83.5-94.9) (84.2-92.0)
II 62 83 139 284
51.0 43.0 69.7 57.7
(38.1-64.4) (32.6-54.3) (60.9-77.8) (51.5-63.9)
III 11 34 51 96
38.9 40.5 46.8 43.6
(16.2-69.2) (25.3-58.3) (33.1-61.5) (33.7-54.4)
Age group (years)
15-44 62 60 113 235
73.2 50.5 82.2 71.7
(60.9-82.8) (38.1-62.9) (73.9-88.3) (65.6-77.2)
45-64 97 104 158 359
71.7 64.9 70.8 69.4
(61.6-80.4) (55.0-74.0) (63.0-77.8) (64.2-74.2)
65-74 35 28 53 116
72.5 66.3 77.6 73.3
(53.4-88.6) (45.3-85.2) (61.8-90.8) (62.7-82.9)
75+ 12 1 15 28
100.0 - 62.6 82.2
(59.2-130.7) - (31.0-100.5) (54.9-108.1)
Histopathological diagnosis 
squamous cell carcinoma 185 176 300 661
73.7 61.2 76.9 71.8
(66.3-80.3) (53.5-68.6) (71.2-81.9) (67.9-75.4)
adenocarcinoma 14 14 27 55
62.3 60.6 58.4 59.9
(35.5-85.7) (34.6-83.4) (39.2-76.1) (46.0-73.0)
others and NS 7 3 12 22
- - - 77.2
- - - (55.0-92.2)
carcinoma (71.8%). In older age groups, a total for all
the three regions under study, no lower survival rates
were found. However, the Opole voivodship shows the
lowest values for all age groups. This is particularly
noticeable in younger patients, where the difference
between the rates was higher than 20 percent points.
The patients in Warsaw had the highest survival rates
in the disease advancement stages under analysis, in all
the age groups below 75 years (comparisons are more
difficult on elderly patients because of their relatively
small number) and in case of patients with the diagnosis
of squamous cell carcinoma. When compared to other
regions, these differences were especially noticeable in
patients with Stage II and in the age group under 45 yrs.
D i f f e r e n t i a t i o n  o f  t h e r a p e u t i c  m e t h o d s  i n
u s e
Most often, in 356 patients (54%) radiotherapy was
applied (teleradiotherapy and brachytherapy), while 262
patients (nearly 40%) were treated by combined methods
(surgery and radiotherapy in different sequences) and
only 40 patients (6%) received surgery alone. Table IV
presents the radical treatment methods administered,
depending on the disease advancement stage and the
patient’s place of living. In Stage I, nearly 80% of patients
received surgery with adjuvant radiotherapy. In a majority
of patients with Stage II (88.4%) and in all the Stage III
patients, radiotherapy alone was administered as the
treatment method. Radiotherapy alone and radiotherapy
combined with surgery were employed more often in the
Opole voivodship than in other areas (p<0.001). Surgery
as a single method was rarely used, while in the Opole
voivodship it was used exceptionally. Surgery combined
with brachytherapy was prescribed more frequently in
Warsaw than in other regions.
The frequency of the treatment methods correlated
with the patient age. Surgery and surgery combined with
radiotherapy was applied more often to younger women,
while radiotherapy alone (p<0.005) – to older ones. Most
cases of squamous cell carcinoma were treated with
methods involving radiotherapy (55.9% of the patients)
while adenocarcinoma was usually treated with methods
involving surgery (53.1%) (p<0.002).
Tr e a t m e n t  d e l a y
The number of days between cancer diagnosis and the
beginning of treatment was 56.4. The average waiting
time for treatment was dependant on the place of living. It
is summarised in Table V. In the voivodship of Kielce, it
reached, by average, 11 days more, and in Opole – 9 days
more than in Warsaw. Only about 20% of the patients in
the voivodships of Kielce and Opole began their
treatment within 30 days from diagnosis; in Warsaw, the
percentage was 44. A large proportion of patients in the
voivodships of Kielce and Opole (around 40%) waited
for more than 60 days for their treatment to begin. This
figure was lower than 30% in case of Warsaw.
Patients in the voivodships of Kielce and Opole
waited for radiotherapy alone, as opposed to other
methods of treatment (Kielce – 77.7 days, p=0.005; Opole
– 74.1 days, p=0.002). This waiting time in Warsaw was
48.4 days and its duration was not much different from
the waiting time for other treatment methods (p=0.67).
The waiting time for radiotherapy in the voivodships of
Kielce and Opole was about 30 days longer than in
Warsaw (p<0.001).
Patients with Stage I cervical cancer in the Kielce
and Opole voivodships, as well as in Warsaw waited for
treatment for about the same time. However, those with
Stage II in the Kielce voivodship usually waited 33 days
longer and in the Opole voivodships – 22 days longer
than those in Warsaw. This difference was statistically
significant (p=0.002).
Figure 1 shows the 5-year survival rates in relation to
the waiting time for treatment. Patients who waited longer
than 60 days showed survival rates lower than those who
waited a shorter time. This difference was especially
noticeable in patients from the Opole voivodship.
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Table IV. Methods of treatment of cervical cancer patients by place of
living and stage of disease, age group and morphology
Surgery TRT* Surgery Surgery
alone + BT** +TRT + BT
+ BT
Number of patients
%
Place of living
Kielce voivodship 10 68 40 8
7.9 54.0 31.7 6.3
Opole voivodship 1 113 74 5
0.5 58.5 38.3 2.6
Warsaw 29 175 80 55
8.6 51.6 23.6 16.2
Stage of disease (FIGO)
I 37 19 157 65
13.3 6.8 56.5 23.4
II 3 251 27 3
1.1 88.4 9.5 1.1
III 0 96 0 0
0.0 100.0 0.0 0.0
Age group (years)
15-44 21 86 71 29
10.1 41.5 34.3 14.0
45-64 16 174 107 25
5.0 54.0 33.2 7.8
65-74 3 75 15 14
2.8 70.1 14.0 13.1
75+ 0 21 1 0
0.0 95.5 4.5 0.0
Histopathological diagnosis
squamous cell carcinoma 32 3323 166 64
5.4 55.9 27.9 10.8
adenocarcinoma 3 17 26 3
6.1 34.7 53.1 6.1
others and NS 5 7 2 1
33.3 46.7 13.3 6.7
* teleradiotherapy
** brachytherapy
Tr e a t m e n t  t i m e
Table VI presents the number of teleradiotherapy days
calculated for patients treated with irradiation as a stan-
dalone method and in combination with surgery. The
average number of teleradiotherapy days given to patients
receiving irradiation alone and irradiation combined with
surgery was 38.4. This time was differentiated chiefly
because of different treatment protocols used in the
regions involved. The radiotherapy time was between
25.3 days in the voivodship of Kielce to 44.9 days in
Opole, and 38.3 in Warsaw.
Only 3 patients in the voivodship of Kielce were
treated with teleradiotherapy for longer than 35 days,
while it was applied to 67% of patients from the Opole
voivodship, and to 74% of patients in Warsaw.
A comparison of survival rates is presented in Figure
2. The small number of patients in the voivodship of
Kielce who had an extended treatment time did not allow
for a survival rate calculation. The survival rates in the
group of patients in the voivodship of Opole who had
been irradiated longer than 35 days were 15% lower than
those treated with the 7-week regime. This difference
was smaller in Warsaw, reaching only 6%.
Extended teleradiotherapy time in the Opole
voivodship was observed mainly in patients with higher
disease advancement stages. In patients with Stage II
(and not much fewer with Stage III), the time was
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Figure 1. The 5-year relative survival rates of cervical cancer patients by time from diagnosis to begining of
treatment, by place of living
Table V. The number of days from diagnosis to beginning of treatment by place of inhabitation and treatment method
Treatment method Number of patients Average number of days between Standard deviation
diagnosis and beginning of treatment 
Kielce voivodship
surgery alone 4 33.8 9.9
TRT + BT 29 77.7 57.4
surgery + TRT + BT 16 46.1 29.9
surgery + BT 1 31.0 –
all treatment methods 50 63.2 49.7
Opole voivodship
surgery alone 1 41.0 –
TRT + BT 109 74.1 48.4
surgery + TRT + BT 68 41.3 35.1
surgery + BT 5 65.9 37.2
all treatment methods 183 61.5 46.1
Warsaw
surgery alone 27 55.3 63.7
TRT + BT 155 48.4 54.9
surgery + TRT + BT 54 58.1 66.9
surgery + BT 49 56.0 61.5
all treatment methods 295 52.4 59.4
Differences between the regions:
All treatment methods p=0.14
RT only p<0.001
significantly longer than the radiotherapy time of patients
with Stage I (p=0.03). No extended radiotherapy time
depending on the advancement stage was observed in
the voivodship of Kielce and in Warsaw.
M u l t i - v a r i a n t  a n a l y s i s
The results of the multi-variant regression analysis are
shown in Table VII. Risk factors associated with an
increase of the RER include the cancer advancement
stage (p<0.0001), the time between diagnosis and
beginning of treatment exceeding 60 days (p=0.04), and
the place of inhabitation in the voivodships of Opole and
Kielce (p<0.03). Histological diagnosis and patient age
had no significant impact on the prognosis.
A model, testing the effect of teleradiotherapy time
longer than 35 days, shows that RER of death was 1.17,
while the difference in RER was not statistically
significant (p=0.35). On the other hand, the risk resulting
from the disease advancement stage, just like the place of
inhabitation, continued to be significantly high. Also,
models testing the Opole voivodship and Warsaw,
separately, did not reveal the significant role of prolonged
teleradiotherapy time (respectively, p=0.54 and p=0.23).
Discussion
As a result of the Government Programme PR-6 and
CPBR (Central Research and Development Programme)
11,5 “Cancer Control” in the years 1976-1990, a three-
level oncological network was established. It included 12
comprehensive cancer centres for which uniform
treatment criteria were developed [17, 18].
Cervical cancer treatment, except for the less
advanced stages, requires complex methods employing
highly specialised surgery and radiotherapy with vast
experience of the doctors and all the medical personnel.
Radiotherapy is used as a standalone treatment method
and in combination with surgery. It combines irradiation
from external fields and brachytherapy. The principal
idea of radiotherapy is the appropriate application of
available methods in order to administer a proper dose to
the tumour and to the metastatic lymph nodes, and to
reduce the risk of post-treatment complications. It is
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Figure 2. The 5-year relative survival rates of cervical cancer patients treated with radiation upto 35 days vs. treated
longer, by place of living
Table VI. Number of irradiation days in patients treated only with irradiation, and by combined method (radiotherapy + surgery)
Treatment methods Number of patients Average number of days of TRT Standard deviation
Kielce voivodship
RT alone 65 24.6 5.8
surgery + RT 26 27.1 5.4
all 91 25.3 5.8
Opole voivodship
RT alone 112 47.3 12.9
surgery + RT 73 41.3 13.6
all 185 44.9 13.5
Warsaw
RT alone 173 38.3 10.1
surgery + RT 77 38.4 6.5
all 250 38.3 9.1
important to apply the planned dose at the optimum time
because any breaks in irradiation, whatever their reason,
reduce the chance for successful treatment. The combined
treatment may be modified in various ways. Usually, it
begins with surgery, the extent of which is determined
according to individual indications and, then, treatment is
continued in the form of teleradiotherapy and brachy-
therapy. Some cases require brachytherapy as the first
treatment phase preceding surgery, which removes the
reproductive organs together with pelvic lymph nodes
and, whenever indications are present (persisting cancer
focus within the uterine cervix or lymph nodes) followed
by additional teleradiotherapy [19].
Apart from the generally accepted principles, the
choice of the treatment procedure depends on the
patient’s clinical condition and, more often nowadays,
her preference if equally effective methods could be
offered. The study has shown that the applied treatment
methods depended on a high proportion of advanced
disease stages. Radiotherapy predominated as a stan-
dalone method or in combination with surgery. Surgery
was rarely performed alone. It was more frequent among
young women, while older patients would rather receive
radiotherapy as less traumatic. Most patients suffering
from adenocarcinoma received radiotherapy combined
with surgery as a method of choice, while radiotherapy
predominated in treating the squamous cell carcinomas.
Despite improving diagnostic methods, surgical
techniques, and irradiation technology all over the world,
no significant improvement has been seen in the results of
treatment of the cervical cancer patients, especially those
with more advanced stages. The European cervical cancer
average 5-year survival rate in the years 1990-1994 was
62.1% and it grew by as little as 3% in the last decade [5].
Many authors believe that the rate improvement in some
countries has resulted from a better access and efficiency
of prevention programmes [20].
There are, alas, opposite trends as well. The causes
for lower survivals are diverse. Countries which have had
long-time screening programmes are witnessing a growth
of adenocarcinoma with worse prognosing [21]. Waiting
time for treatment in Britain and Canada has become
longer [22, 23]. Transition and economic crisis in post-
communist countries changed their health service systems
and survivals declined as a result of the shrinking
proportion of early detected cancers and less effective
treatment [20]. The 5-year survival rate estimated for
Poland in the 1990s was 48.2%, that is, one of the lowest
in Europe [5].
The results of this study, which deals with patients
who had received radical treatment and are supposed to
be cured. However, even before the treatment was
applied, unequal chances to be cured were noticeable in
the regions under study, since the proportion of early
stages diagnosed were significantly different. The multi-
variant analysis shows that when the disease advances
from Stage I to Stage II, the risk of death grows 5 times. A
higher proportion of patients with cancer in Stage II and
higher can largely explain the low 5-year survival rates
for all the patients and also those belonging to the
youngest age groups in the Opole voivodship. However,
differences in survivals calculated for stages require
special attention.
The 5-years survivals of patients with Stage I cervical
cancer living in the analysed regions are similar and are
not much different from those published in the FIGO
Report, which used data on 11,620 patients and an
analogous period of time [24]. We also need to note that
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Table VII. Relative excessive risk of death (RER) by stage of disease, age group, morphology, place of living, time from diagnosis to beginning
of treatment and number of irradiation days
RER 95% CI p
Stage of disease (FIGO)
I 1.00
II 4.83 (3.18-7.35) <0.0001
III 7.52 (4.66-12.14) <0.0001
Histopathological diagnosis
squamous cell carcinoma 1.00
adenocarcinoma 1.42 (0.82-2.43) 0.21
Age group (years)
15-44 1.00
45-64 0.82 (0.58-1.15) 0.26
>64 0.76 (0.50-1.16) 0.21
Place of living
Warsaw 1.00
Kielce voivodship 1.87 (1.13-3.08) 0.02
Opole voivodship 1.73 (1.25-2.39) 0.001
Days between cancer diagnosis and beginning of treatment
<30 1.00
30-60 0.96 (0.64-1.44) 0.84
>60 1.49 (1.03-2.16) 0.04
Days of radiotherapy
<35 1.00
>35 1.17 (0.84-1.63) 0.35
survivals of Warsaw patients with Stages II and III were
not significantly different from those included in the
Report (there are certain methodological differences in
calculating survivals for the FIGO Report, hence the
comparisons are not precise). Therefore, the low survival
rates in Stage II in the Opole voivodship (27 percent
points lower than in Warsaw) and in the Kielce voivodship
(19 percent points lower) are even more concern.
The reason for this seems to lie in un-uniform
diagnostic and treatment procedures. The patients were
treated according to various protocols in many
oncological departments. Patients from the Kielce
voivodship were usually referred for radiotherapy to the
Maria Sk∏odowska-Curie Cancer Centre and Institute of
Oncology in Cracow, and, sometimes, also to Gliwice,
¸ódê, Rzeszów and Warsaw. Those from the Opole
voivodship, were usually sent to a specialist oncological
department at the Wojewódzki Szpital Zespolony, Opole
(Currently: Opolskie Centrum Onkologii), and those from
Warsaw were usually treated at the Maria Sk∏odowska-
Curie Cancer Centre and Institute of Oncology in
Warsaw. A small number of patients living in Warsaw
received brachytherapy procedures at the Grochowski
Hospital in Warsaw. And also the Central Clinical
Hospital of the Department of National Defence offered
teleradiotherapy treatment.
The presented results show, that the standard of
treatment was not equal everywhere, resulting in a longer
waiting time and a longer time of teleradiotherapy.
Treatments were modified and intervals caused by the
patients’ health condition, post-surgery healing, irra-
diation complications, co-morbidity (such as various
infectious diseases, diabetes, circulatory failures,
glaucoma, injuries in road accidents and by reasons of
organisational nature, among them, waiting lists, long
week-ends, other technical reasons like equipment
breakdowns, service, and travel fatigue.
As was shown by the study, the proportion of
patients waiting for treatment for more than 30 days was
large – 80% in the Opole and Kielce voivodships, and
55% in Warsaw. These patients waited for teleradio-
therapy as the first treatment. Also, patients with higher
disease advancement stages waited longer for radio-
therapy. The multi-variant analysis shows that waiting for
treatment for over 60 days increases the RER of death by
nearly 50%.
The study has also shown a small, statistically
insignificant, risk increase associated with the number of
teleradiotherapy days being higher than 35. Adjusting for
the stage of disease, the waiting time for treatment,
patient’s age, and histological diagnosis, the place of living
was still an important risk factor increasing RER by about
80% in the patients from the Kielce and Opole voi-
vodships as compared to those from Warsaw. According
to UICC classification, it should be considered as an
environmentally related risk factor, i.e. related to the
treatment standards, mainly with the radiotherapy
duration, the use of brachytherapy, and the frequency of
treatment complications [10].
The adverse effect of delayed cancer treatment is
known and was often studied in Poland. Following WHO
estimations, M. Pawlicki in 1995 assessed that Poland
might expect a minimum 15% growth of cure rate by
2004 as a result of early detection and better health
service organisation, combined with better diagnostic
equipment. In his estimations, Pawlicki relied, beside
other sources, on his own studies, which assessed the
delay in providing specialised cancer treatment. General
Practitioners were responsible for 9 month delays,
prolonged diagnostic procedure at a local hospital –
average 6 weeks, and waiting for treatment at a cancer
clinic in some voivodships – another 3-6 weeks. Delays
resulting from wrong diagnosis were even longer [25, 26].
The time between diagnosis and beginning of
treatment, the so called “time lost”, is one of the most
important prognostic factors, especially for patients with
fast proliferating cancers, cervical cancer being one of
them [22, 27]. The role of this factor is especially
significant in advanced stages of the disease [28, 29].
The importance of the “time lost” was also demon-
strated by O’Rourke et al., in a prospective study
investigating the impact of the “waiting list” for radical
radiotherapy in lung cancer patients. The investigators
established that 21% of patients “lost” eligibility for
radical treatment after waiting the average 94 days [30].
Also, Wyatt R.M. et al., confirmed the unfavourable
effect of delay in providing treatment by using
mathematical models. Considering the therapeutic effect
in slowing down the tumour growth and doubling the
treatment time, they demonstrated that a 1-2 month delay
in treatment has a significant impact on the probability of
disease local recurrence in cervical cancer patients [29].
Shortage of qualified personnel, shortage of treat-
ment equipment, growing cost of treatment and financial
scarcity, suffered by the health sector are not only a Polish
problem. Despite a declining number of cervical cancer
patients in many countries, the waiting lists of patients
are becoming longer, though the treatment standards are
improving at the same time.
Realizing the adverse effect of treatment delays
and the scale of this phenomenon in many countries,
researchers and health service system decision makers
began giving more attention to the problem. They
ventured to propose optimum solutions, which were
a compromise between the “time lost” and the cost of
treatment. As the result of such analyses, the Joint
Council of Clinical Oncology, and the Committee on
Standards of the Canadian Association of Radiation
Oncologists were among those authorities which recom-
mended commencing radical treatment within 14 days
after diagnosis and by no means later than after 28 days
[23, 31].
These recommendations provided a basis for further
studies on the size and role of this problem. It was
estimated that the waiting time for treatment of most
cancers in the United States was much shorter than in
Canada [32]. The authors also report that the recom-
mendations were hardly ever obeyed in the UK. The
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waiting time for radiotherapy in 2001 was almost three
times longer than in 1996 and it grew to 35 days. Only
12% of patients received radiotherapy before 4 weeks
from being diagnosed for cancer. These facts are caused
by the shortage of treatment equipment and personnel
[22, 23].
The recent decade has provided ample evidence that
extension of irradiation time by more than 7 weeks has
a negative effect on radically treated cancer patients’
survival. Fyles and Lanciano estimate that every day of
treatment extension increases the probability of local
recurrence by 1%, especially in higher disease advan-
cement stages [33, 34]. Similar results were obtained by
Karolewski in his study of a group of patients treated at
the Maria Sk∏odowska-Curie Cancer Centre and Institute
of Oncology in Kraków [35]. At the same time, many
reports say that excessive reduction of irradiation time
not only fails to improve the treatment results but also
reduces its efficiency and encourages complications, many
of them quite serious [11, 36].
Low survival rates of cervical cancer patients in the
UK, various treatment procedures, and prolonged
treatment motivated the Royal College of Radiologists
(RCR) in 1996 to recommend procedures intended
to strengthen compliance with planned radiotherapy
time. RCR recommended to compensate for breaks in
treatment by twice-daily irradiation, or on days off work,
or increasing the total or fractionated doses [37]. The
recommendations generated a measurable improvement
in treatment standards. In 2001, the rate of patients
treated with continuous teleradiotherapy was 94% and
it grew almost five times in relation to 1996, and the total
irradiation time was cut down to 39 days [22].
However, the waiting time for radiotherapy became
longer at the same time. Coles at al., used a mathematical
model to find out that the consequences of prolonged
waiting time are not compensated by shorter radio-
therapy. The effect of waiting for treatment is very
important in cervical cancer patients, especially those
with higher advancement stages [22]. Authors stress that
recommendations given to-date are arbitrary and tempo-
rary because they do not allow for the individual time of
cancer growth and its sensitiveness to radiation at
different phases of disease. They emphasise an urgent
need to develop national treatment standards based on
multi-centre clinical studies and a systematic exchange
of experience, also, in the area of long-term treatment
results and radiotherapy complications in each hospital
working on the problem [12]. However, until a measura-
ble improvement is reached in the treatment standard,
careful monitoring of the patients on the “waiting list”
is indispensable and treatment must be delivered sooner,
depending on the individual indications [22].
Owing to financial resources provided by the State
Committee for Scientific Research, Kielce, Opole, and
Warsaw have set up modern, population-based data bases
of cervical cancer patients which store data on selected
prognostic factors and treatment procedures. The data
resource gathered by them allowed comparative studies
and conclusions pointing to the most important short-
comings in treating cervical cancer patients living in the
regions under study. A study of population data obtained
from Cancer Registries avoided the selection bias, which
contaminates other studies which use data from hospitals.
Here, the methodology ensured comparativeness of the
results obtained and, therefore, the identified regional
differences in the cervical cancer patients’ chance for
cure were real.
Conclusions
1. Regional studies have shown considerable diversity in
the 5-year survival rates of cervical cancer patients.
This refers to patients with Stage II and the youngest
age groups. The unfavourable proportion of the
disease advancement stages, which is the most
important prognostic factor, only in part explains the
poor treatment results found in the area of former
Opole voivodship.
2. The long waiting time for treatment (longer than 60
days on the average), particularly for radiotherapy,
affecting most of patients from the Kielce and Opole
voivodships suffering from advanced cancers, is
a factor significantly deteriorating the prognosis and, to
some extent, explains the regional differentiation of
survival rates.
3. The number of teleradiotherapy days being higher
than 35 had no significant effect on the death risk.
Lower 5-year survival rates in the group of patients
with prolonged teleradiotherapy in the Opole
voivodship and Warsaw depended on the disease
advancement stage and the time of waiting for the
treatment.
4. The place of inhabitation and, therefore, also the place
of treatment in the Kielce and Opole voivodships,
continued to be independent prognostic factors (RER
higher than in Warsaw by about 80%) and it seems to
be related to non-uniform treatment standards. This
requires further studies leading to the development
of national standards for cervical cancer treatment.
5. The study confirms that effective prevention, which
improves the proportion of early cancer stages, is the
most successful method of cervical cancer control in
the population. Advanced cancers are much more
difficult to treat, especially in a situation of equipment
shortage and long waiting time for treatment.
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